Showing 2681-2690 of 6036 results for "".
- Alcon Introduces Reusable Toric Lens with Launch of TOTAL30 for Astigmatismhttps://modernod.com/news/alcon-introduces-reusable-toric-lens-with-launch-of-total30-for-astigmatism/2481324/Alcon announced plans to launch TOTAL30 for Astigmatism, which the company calls the first-and-only reusable contact lens with water gradient material for astigmatic contact lens wearers. Using Alcon’s proprietary water gradient material, first introduced with DAILIES TOTAL1&
- Eversight and the Department of Health–Abu Dhabi Partner to Establish UAE’s First Eye and Tissue Bankhttps://modernod.com/news/eversight-and-the-department-of-health-abu-dhabi-partner-to-establish-uaes-first-eye-and-tissue-bank/2481291/Global nonprofit eye bank Eversight and the Department of Health – Abu Dhabi (DoH) are partnering to establish the first eye and tissue bank in the United Arab Emirates (UAE). The
- Bausch + Lomb Receives 510(k) Clearance from FDA for Biotrue Hydration Boost Contact Lens Rehydrating Dropshttps://modernod.com/news/bausch-lomb-receives-510k-clearance-from-fda-for-biotrue-hydration-boost-contact-lens-rehydrating-drops/2481290/Bausch + Lomb announced that it has received 510(k) clearance from the FDA for Biotrue Hydration Boost Contact Lens Rehydrating drops, a preservative-free multi-dose rehydrating drop for use with soft and rigid gas permeable contact lenses. “We ar
- Amgen to Buy Horizon Therapeutics in Deal Worth $27.8 Billionhttps://modernod.com/news/amgen-to-buy-horizon-therapeutics-in-deal-worth-278-billion/2481288/Amgen announced it is acquiring rare disease drug company Horizon Therapeutics, maker eye disease drugs Tepezza and Uplizna, in a deal valued at $27.8 billion. The company will pay $116.50 in cash per share, a premium of 19.7% to Horizon’s last closing price. Tepezza (teprotumumab
- Re-Vana Therapeutics Raises $11.9 Million to Advance Drug Delivery Productshttps://modernod.com/news/re-vana-therapeutics-raises-119-million-to-advance-drug-delivery-products/2481266/Re-Vana Therapeutics announced the closure of its Series A round with $11.9 million in funding, an oversubscription of $4 million. The proceeds will advance the development of Re-Vana's novel and proprietary photo-crosslinked EyeLief, EyeLief-SD, and OcuLief 
- Kala Pharmaceuticals Submits of Investigational NDA for KPI-012 for the Treatment of Persistent Corneal Epithelial Defecthttps://modernod.com/news/kala-pharmaceuticals-submits-of-investigational-nda-for-kpi-012-for-the-treatment-of-persistent-corneal-epithelial-defect/2481262/Kala Pharmaceuticals announced the submission of an investigational new drug application (NDA) to the FDA for KPI-012 for the treatment of persistent corneal epithelial defect (PCED). Subject to acceptance of the IND by the FDA, Kala remains on-track to initiate a phase 2b cli
- New UCI-Led Study Shows Repeated Stress Accelerates Aging of the Eyehttps://modernod.com/news/new-uci-led-study-shows-repeated-stress-accelerates-aging-of-the-eye/2481260/New research from the University of California, Irvine, suggests aging is an important component of retinal ganglion cell death in glaucoma, and that novel pathways can be targeted when designing new treatments for glaucoma patients. The study, titled, “
- FDA Grants Breakthrough Therapy Designation for Iveric Bio's Avacincaptad Pegol for Geographic Atrophyhttps://modernod.com/news/fda-grants-breakthrough-therapy-designation-for-iveric-bios-avacincaptad-pegol-for-geographic-atrophy/2481251/Iveric bio announced that the FDA has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). To date, A
- Study: Vision Impairment is Associated with as Many as 100,000 US Dementia Caseshttps://modernod.com/news/study-vision-impairment-is-associated-with-as-many-as-100000-us-dementia-cases/2481238/Up to 100,000 US dementia cases could have potentially been prevented with improved eye care, according to a National Institute on Aging (NIA)-funded study published in JAMA Neurology. While the search for breakthrough drugs or interventions that could be treatments f
- FDA Accepts Tarsus' New Drug Application for TP-03 for Treatment of Demodex Blepharitishttps://modernod.com/news/fda-accepts-tarsus-new-drug-application-for-tp-03-for-treatment-of-demodex-blepharitis/2481235/As part of its third quarter earnings report, Tarsus Pharmaceuticals announced that the FDA has accepted the company's new drug application (NDA) for TP-03 for the treatment of Demodex blepharitis. The Prescription Drug User Fee Act (PDUFA) target action da